SOD1 and amyotrophic lateral sclerosis: A Phase I clinical trial to assess the pharmacokinetics of Cu(II)ASTM in ALS patients has been completed (NCT02870634) and another study (NCT04082832) is ongoing to assess its efficacy without; however, selecting for SOD1‐ALS patients in which drug efficacy has been proven in the respective mouse model.